SCHEMBL7342188

SCHEMBL7342188

COc1ccc(S(=O)(=O)N(CC(=O)NO)Cc2cc3c(cc2Cl)OCO3)cc1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP3 P08254 6/20 0.58
MMP13 P45452 4/20 0.58
MMP1 P03956 3/20 0.58
MMP8 P22894 3/20 0.58
MMP2 P08253 2/20 0.58
MMP9 P14780 2/20 0.58
CA2 P00918 1/20 0.58
MMP7 P09237 2/20 0.56
MMP12 P39900 2/20 0.56
MEP1B Q16820 5/20 0.56
ADAM10 O14672 1/20 0.55
ADAM17 P78536 1/20 0.55
MEP1A Q16819 1/20 0.55
BMP1 P13497 2/20 0.54
MAPT P10636 3/20 0.52
ALDH1A1 P00352 2/20 0.52
KEAP1 Q14145 1/20 0.49
HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7340819 0.89 KEAP1 (0.64) MEP1BBMP1MAPTALDH1A1KEAP1
SCHEMBL7344381 0.85 ALDH1A1 (0.58) MMP13MMP1MMP8MMP2MMP9
SCHEMBL7350084 0.85 MEP1B (0.65) MMP3MMP13MMP1MMP8MMP2
SCHEMBL7344978 0.78 BMP1 (0.57) MMP1MMP8BMP1
SCHEMBL7344980 0.78 BMP1 (0.57) MMP1MMP8BMP1
SCHEMBL7348906 0.77 MEP1B (0.86) MMP3MMP13MMP1MMP8MMP2
SCHEMBL5577038 0.77 MEP1B (0.78) MMP3MMP13MMP1MMP8MMP2
SCHEMBL7111453 0.76 BMP1 (0.63) MMP1MMP8MEP1BBMP1
SCHEMBL7338644 0.74 MEP1B (0.81) MMP3MMP13MMP1MMP8MMP2
SCHEMBL7342781 0.74 BMP1 (0.67) MMP1MMP8BMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0766672-B1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS NOVARTIS AG (CH) 2000-10-04 EP disclosed
EP-0606046-B1 Arylsulfonamido-substituted hydroxamic acids CIBA GEIGY AG (CH) 1997-10-08 EP disclosed
US-5646167-A ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT CIBA-GEIGY CORPORATION (US) 1997-07-08 US disclosed
EP-0766672-A1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS Novartis AG (CH) 1997-04-09 EP disclosed
WO-1996040101-A1 CERTAIN ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS FOR THE TREATMENT OF CERTAIN TUMORS NOVARTIS AG (CH) 1996-12-19 WO disclosed
US-5552419-A METALLOPROTEINASE INHIBITORS CIBA-GEIGY CORPORATION (US) 1996-09-03 US disclosed
US-5506242-A METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA CIBA-GEIGY CORPORATION (US) 1996-04-09 US disclosed
WO-1996000214-A1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS CIBA-GEIGY AG (CH) 1996-01-04 WO disclosed
US-5455258-A Useful as inhibitors of matrix-degrading metalloproteinase enzymes such as stromelysin and/or collegenase CIBA-GEIGY CORPORATION (US) 1995-10-03 US disclosed
EP-0606046-A1 Arylsulfonamido-substituted hydroxamic acids CIBA-GEIGY AG (CH) 1994-07-13 EP disclosed